Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’

Authors :: Masatoshi Kudo
Kaoru Tsuchiya
Tatsuya Yamashita
Hironori Koga
Yuki Nakagawa
Masafumi Ikeda
Source :: Liver Cancer (2024)
Publication Year :: 2024
Publisher :: Karger Publishers, 2024.

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools